Amgen is investing over $600 million in a new science and innovation center at its global headquarters in Thousand Oaks, California, reflecting its commitment to in-house U.S.-based research and development. Construction is to begin in the third quarter of 2025 and create hundreds of American jobs.
The lab is designed to bring together researchers, engineers, and scientists across diverse fields, accelerating discovery of the next generation of therapies for patients suffering from disabling diseases. With advanced automation and digital technologies, the lab will provide scientists with the equipment and space they require to drive innovation in biotechnology.
This new building will give our teams the open workspace and tools they need to chart the course of discovery and develop medicines that have the potential to improve human health,” said Amgen Chairman and CEO Robert A. Bradway. “As a biopharmaceutical American company, we are dedicated to continuing to invest in American science and innovation.”
Company’s decades-long track record of domestic investment
The Thousand Oaks project extends the company’s long tradition of US investments, dating back decades. Amgen has spent more than $40 billion in R&D and manufacturing since the Tax Cuts and Jobs Act of 2017, and more than $5 billion on direct domestic capital expenditures. It has been complemented by pro-growth tax policy, recently highlighted by the One Big Beautiful Bill Act of 2025, enabling the company to expand its high-tech businesses here at home.
The new facility will add to Amgen’s global network of facilities, leveraging decades of manufacturing expertise and technological sophistication. It follows other recent U.S. expansions, including a $900 million redevelopment of its Central Ohio plant and a $1 billion investment to construct a second Holly Springs facility in North Carolina.
Headquartered in Thousand Oaks for more than 45 years, Amgen continues to view its California operations as a cornerstone of its innovation platform, providing cutting-edge scientific expertise and significant economic impact to the state. As more companies seek to solidify their presence in the U.S., Infinite Reality, now officially Napster and plans to construct a 60-acre flagship campus in Fort Lauderdale, which will serve as a cutting-edge center for immersive technology and entertainment.
Amgen New Science and Innovation Center: Project Factsheet
Project Overview
Amgen is investing over $600 million to establish a new science and innovation hub at its global headquarters in Thousand Oaks, California, marking a significant expansion of its U.S.-based research and development capabilities.
Key Project Details
Investment Amount: $600+ million
Location: Thousand Oaks, California (Amgen Global HQ)
Construction Timeline: Q3 2025 start
Employment Impact: Hundreds of new American jobs
Facility Features
The state-of-the-art center will include:
Advanced automation and digital technologies
Collaborative spaces for cross-disciplinary research
Integrated environment for researchers, engineers, and scientists
Next-generation biotechnology research capabilities
Strategic Objectives
Accelerate discovery of breakthrough therapies for serious illnesses
Foster multidisciplinary collaboration and innovation
Strengthen Amgen’s position in biotechnology research
Support development of next-generation medical treatments
Investment Context
This project represents part of Amgen’s broader $40+ billion commitment to U.S. manufacturing and R&D since 2017, including:
Over $5 billion in direct U.S. capital expenditures
$900 million manufacturing facility upgrade in Central Ohio
$1 billion second plant investment in Holly Springs, North Carolina
Economic Impact
Reinforces 45+ year commitment to California operations
Creates substantial regional economic impact
Strengthens U.S. biotechnology sector
Supports American science and innovation leadership
